Ticagrelor potentiates adenosine-induced stimulation of neutrophil chemotaxis and phagocytosis

Vascular Pharmacology

Volumn 71, Issue , 2015, Pages 201-207

  Alsharif, Khalaf F ^a   Thomas, Mark R ^a   Judge, Heather M ^a   Khan, Haroon ^a   Prince, Lynne R ^a   Sabroe, Ian ^a   Ridger, Victoria C ^a   Storey, Robert F ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

Adenosine; Dipyridamole; Erythrocytes; Neutrophils; Ticagrelor

Indexed keywords

8 CYCLOPENTYL 1,3 DIPROPYLXANTHINE; ADENOSINE; ADENOSINE A1 RECEPTOR; CANGRELOR; DIPYRIDAMOLE; EQUILIBRATIVE NUCLEOSIDE TRANSPORTER 1; INTERLEUKIN 8; TICAGRELOR;

ARTICLE; CHEMOTAXIS ASSAY; CONTROLLED STUDY; ERYTHROCYTE; HOST RESISTANCE; HUMAN; HUMAN CELL; IMMUNOSTIMULATION; IN VITRO STUDY; LUNG INFECTION; NEUTROPHIL; NEUTROPHIL CHEMOTAXIS; NORMAL HUMAN; PHAGOCYTOSIS; PRIORITY JOURNAL; STREPTOCOCCUS PNEUMONIAE; ANALOGS AND DERIVATIVES; CHEMOTAXIS; DOSE RESPONSE; DRUG EFFECTS; DRUG POTENTIATION; PHYSIOLOGY;

ADENOSINE; CHEMOTAXIS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; HUMANS; NEUTROPHILS; PHAGOCYTOSIS;

EID: 84937973295     PISSN: 15371891     EISSN: 18793649     Source Type: Journal    
DOI: 10.1016/j.vph.2015.02.006     Document Type: Article

References (39)

1. Van Giezen J.J., Sidaway J., Glaves P., et al. Ticagrelor inhibits adenosine uptake in vitro and enhances adenosine-mediated hyperemia responses in a canine model. J Cardiovasc Pharmacol Ther 2012, 17:164-172.
2. Armstrong D., Summers C., Ewart L., et al. Characterization of the adenosine pharmacology of ticagrelor reveals therapeutically relevant inhibition of equilibrative nucleoside transporter 1. J Cardiovasc Pharmacol Ther 2014, 19:209-219.
3. Wallentin L., Becker R.C., Budaj A., et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009, 361:1045-1057.
4. Gurbel P.A., Bliden K.P., Butler K., et al. Randomized double-blind assessment of the ONSET and OFFSet of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study. Circulation 2009, 120:2577-2585.
5. Storey R.F., Angiolillo D., Patil S., et al. Inhibitory effects of ticagrelor compared to clopidogrel on platelet function in patients with acute coronary syndromes: the PLATO PLATELET substudy. J Am Coll Cardiol 2010, 56:1456-1462.
6. Bonello L., Laine M., Kipson N., et al. Ticagrelor increases adenosine plasma concentration in patients with an acute coronary syndrome. J Am Coll Cardiol 2014, 63:872-877.
7. Wittfeldt A., Emanuelsson H., Brandrup-Wognsen G., et al. Ticagrelor enhances adenosine-induced coronary vasodilatory responses in humans. J Am Coll Cardiol 2013, 61:723-727.
8. Alexopoulos D., Moulias A., Koutsogiannis N., et al. Differential effect of ticagrelor versus prasugrel on coronary blood flow velocity in patients with non-ST-elevation acute coronary syndrome undergoing percutaneous coronary intervention: an exploratory study. Circ Cardiovasc Interv 2013, 6:277-283.
9. Nanhwan M.K., Ling S., Kodakandla M., et al. Chronic treatment with ticagrelor limits myocardial infarct size: an adenosine and cyclooxygenase-2-dependent effect. Arterioscler Thromb Vasc Biol 2014, 34:2078-2085.
10. Nylander S., Femia E.A., Scavone M., et al. Ticagrelor inhibits human platelet aggregation via adenosine in addition to P2Y12 antagonism. J Thromb Haemost 2013, 11:1867-1876.
11. Storey R.F., James S.K., Siegbahn A., et al. Lower mortality following pulmonary adverse events and sepsis with ticagrelor compared to clopidogrel in the PLATO study. Platelets 2013, 25:517-525.
12. Varenhorst C., Alström U., Scirica B.M., et al. Factors contributing to the lower mortality with ticagrelor compared with clopidogrel in patients undergoing coronary artery bypass surgery. J Am Coll Cardiol 2012, 60:1623-1630.
13. Varenhorst C., Alström U., Braun O.Ö., et al. Causes of mortality with ticagrelor compared with clopidogrel in acute coronary syndromes. Heart 2014, 100:1762-1769.
14. Eltzschig H.K., Sitkovsky M.V., Robson S.C. Purinergic signaling during inflammation. N Engl J Med 2012, 367:2322-2333.
15. Barletta K.E., Ley K., Mehrad B. Regulation of neutrophil function by adenosine. Arterioscler Thromb Vasc Biol 2012, 32:856-864.
16. Baldwin S., Beal P., Yao S.M., et al. The equilibrative nucleoside transporter family, SLC29. Pflugers Arch - Eur J Physiol 2004, 447:735-743.
17. Gresele P., Arnout J., Deckmyn H., et al. Mechanism of the antiplatelet action of dipyridamole in whole blood: modulation of adenosine concentration and activity. Thromb Haemost 1986, 55:12-18.
18. Nolan S., Dixon R., Norman K., et al. Nitric oxide regulates neutrophil migration through microparticle formation. Am J Pathol 2008, 172:265-273.
19. Kawa S., Kimura S., Hakomori S., et al. Inhibition of chemotactic motility and trans-endothelial migration of human neutrophils by sphingosine 1-phosphate. FEBS Lett 1997, 420:196-200.
20. Sano H., Hsu D.K., Apgar J.R., et al. Critical role of galectin-3 in phagocytosis by macrophages. J Clin Invest 2003, 112:389-397.
21. Lohse M.J., Klotz K.N., Lindenbornfotinos J., et al. 8-Cyclopentyl-1,3-dipropylxanthine (DPCPX) - a selective high-affinity antagonist radioligand for A1 adenosine receptors. Naunyn-Schmiedebergs Arch Pharmacol 1987, 336:204-210.
22. Zocchi C., Ongini E., Conti A., et al. The non-xanthine heterocyclic compound SCH 58261 is a new potent and selective A2a adenosine receptor antagonist. J Pharmacol Exp Ther 1996, 276:398-404.
23. Jacobson K.A., Gao Z.-G. Adenosine receptors as therapeutic targets. Nat Rev Drug Discov 2006, 5:247-264.
24. Frevert C.W., Wong V.A., Goodman R.B., et al. Rapid fluorescence-based measurement of neutrophil migration in vitro. J Immunol Methods 1998, 213:41-52.
25. Cronstein B.N., Levin R.I., Philips M., et al. Neutrophil adherence to endothelium is enhanced via adenosine A1 receptors and inhibited via adenosine A2 receptors. J Immunol 1992, 148:2201-2206.
26. Chen Y., Corriden R., Inoue Y., et al. ATP release guides neutrophil chemotaxis via P2Y2 and A3 receptors. Science 2006, 314:1792-1795.
27. Zhang Y., Zhang Q., Zhang J., et al. Dipyridamole enhances inhibitory effect of adenosine on neutrophils in human peripheral blood. J Nanjing Med Univ 2008, 22:243-245.
28. McDonald B., Pittman K., Menezes G.B., et al. Intravascular danger signals guide neutrophils to sites of sterile inflammation. Science 2010, 330:362-366.
29. Cronstein B.N. Adenosine, an endogenous anti-inflammatory agent. J Appl Physiol 1994, 76:5-13.
30. Inoue Y., Chen Y., Hirsh M.I., et al. A3 and P2Y2 receptors control the recruitment of neutrophils to the lungs in a mouse model of sepsis. Shock 2008, 30:173-177.
31. van der Hoeven D., Wan T.C., Auchampach J.A. Activation of the A3 adenosine receptor suppresses superoxide production and chemotaxis of mouse bone marrow neutrophils. Mol Pharmacol 2008, 74:685-696.
32. Mulloy D.P., Sharma A.K., Fernandez L.G., et al. Adenosine A3 receptor activation attenuates lung ischemia-reperfusion injury. Ann Thorac Surg 2013, 95:1762-1767.
33. Salmon J.E., Cronstein B.N. Fc gamma receptor-mediated functions in neutrophils are modulated by adenosine receptor occupancy. A1 receptors are stimulatory and A2 receptors are inhibitory. J Immunol 1990, 145:2235-2240.
34. Zalavary S., Stendahl O., Bengtsson T. The role of cyclic AMP, calcium and filamentous actin in adenosine modulation of Fc receptor-mediated phagocytosis in human neutrophils. Biochim Biophys Acta 1994, 1222:249-256.
35. Chello M., Mastroroberto P., Malta E., et al. Inhibition by dipyridamole of neutrophil adhesion to vascular endothelium during coronary bypass surgery. Ann Thorac Surg 1999, 67:1277-1282.
36. Öhman J., Kudira R., Albinsson S., et al. Ticagrelor induces adenosine triphosphate release from human red blood cells. Biochem Biophys Res Commun 2012, 418:754-758.
37. 12 receptor. Curr Pharm Des 2006, 12:1255-1259.
38. de Stoppelaar S.F., van 't Veer C., van der Poll T. The role of platelets in sepsis. Thromb Haemost 2014, 112:666-677.
39. Csoka B., Nemeth Z.H., Rosenberger P., et al. A2B adenosine receptors protect against sepsis-induced mortality by dampening excessive inflammation. J Immunol 2010, 185:542-550.